0000950170-23-048440.txt : 20230915
0000950170-23-048440.hdr.sgml : 20230915
20230915174727
ACCESSION NUMBER: 0000950170-23-048440
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230913
FILED AS OF DATE: 20230915
DATE AS OF CHANGE: 20230915
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HAMED KAMAL
CENTRAL INDEX KEY: 0001946366
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38266
FILM NUMBER: 231259669
MAIL ADDRESS:
STREET 1: 675 MASSACHUSETTS AVENUE, 14TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Spero Therapeutics, Inc.
CENTRAL INDEX KEY: 0001701108
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 675 MASSACHUSETTS AVENUE
STREET 2: 14TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 857-242-1600
MAIL ADDRESS:
STREET 1: 675 MASSACHUSETTS AVENUE
STREET 2: 14TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: Spero Therapeutics, LLC
DATE OF NAME CHANGE: 20170316
4
1
ownership.xml
4
X0508
4
2023-09-13
0001701108
Spero Therapeutics, Inc.
SPRO
0001946366
HAMED KAMAL
C/O SPERO THERAPEUTICS, INC.
675 MASSACHUSETTS AVENUE, 14TH FLOOR
CAMBRIDGE
MA
02139
false
true
false
false
Chief Medical Officer
false
Common Stock
2023-09-13
4
S
false
39496
1.27
D
576461
D
The reported transaction is a sale of common stock effected to cover tax withholding obligations in connection with the vesting of (i) restricted stock units ("RSUs") that were granted to the Reporting Person on September 12, 2022 pursuant to a "sell to cover" provision included in the RSU Agreement and (ii) performance-based restricted stock units ("PSUs") that were granted to the Reporting Person on August 4, 2022, subject to the achievement of certain pre-established performance criteria, which the Board of Directors of the Issuer determined had been 100% met on June 12, 2023, pursuant to a "sell to cover" provision included in the PSU Agreement.
The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $1.27 to $1.295 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
/s/ Tamara Joseph, Attorney-in-Fact for Kamal Hamed
2023-09-15